GlassScriptPhysician profile
Robert C Galagan
NPI 1538253901
$715.90
in general payments reported to CMS, 2019-2025
11 companies · $15.57 in 2025
The $15.57 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.49 · 2023: $294 · 2024: $311 · 2025: $15.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.82 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $124.19 | 2023-2024 | |
| Corcept Therapeutics | $111.26 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $62.95 | 2023-2024 | Recorlev |
| Amgen INC. | $61.09 | 2023-2024 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $43.97 | 2024 | |
| Abbott Laboratories | $41.23 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $29.09 | 2023 | |
| Dexcom, INC. | $28.33 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $17.71 | 2019 | |
| Ascendis Pharma Endocrinology INC | $17.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.